<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514500</url>
  </required_header>
  <id_info>
    <org_study_id>NN8640-3915</org_study_id>
    <secondary_id>U1111-1119-0539</secondary_id>
    <secondary_id>2011-000146-38</secondary_id>
    <nct_id>NCT01514500</nct_id>
  </id_info>
  <brief_title>First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects</brief_title>
  <official_title>First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability,
      pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the
      effect of the investigated drug on the body) of NNC0195-0092 (somapacitan) compared to
      placebo in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2012</start_date>
  <completion_date type="Actual">March 18, 2013</completion_date>
  <primary_completion_date type="Actual">March 18, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (Single Dose)</measure>
    <time_frame>From first administration of trial product and up until day 40</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (Multiple Dose)</measure>
    <time_frame>From first administration of trial product and up until day 49</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the NNC0195-0092 (somapacitan) serum concentration-time curve</measure>
    <time_frame>From 0 to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the NNC0195-0092 (somapacitan) serum concentration-time curve (SD part only)</measure>
    <time_frame>From 0-240 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the NNC0195-0092 (somapacitan) serum concentration-time curve (SD part only)</measure>
    <time_frame>up to day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) for NNC0195-0092 (somapacitan)</measure>
    <time_frame>up to day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the IGF-I (insulin-like growth factor-I) serum concentration-time curve</measure>
    <time_frame>From 0-168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the IGF-I (insulin-like growth factor-I) serum concentration-time curve (SD part only)</measure>
    <time_frame>From 0-240 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) for IGF-I</measure>
    <time_frame>up to day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the IGFBP-3 (insulin-like growth factor binding protein-3) serum concentration-time curve</measure>
    <time_frame>From 0-168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the IGFBP-3 (insulin-like growth factor binding protein-3) serum concentration-time curve (SD part only)</measure>
    <time_frame>From 0-240 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) for IGFBP-3</measure>
    <time_frame>up to day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injection site reactions</measure>
    <time_frame>From first administration of trial product and up until day 40 (SD part)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injection site reactions</measure>
    <time_frame>From first administration of trial product and up until day 49 (MD part)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Adult Growth Hormone Deficiency</condition>
  <condition>Growth Hormone Deficiency in Children</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose (MD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somapacitan</intervention_name>
    <description>Administered s.c. (subcutaneously, under the skin)</description>
    <arm_group_label>Single dose (SD)</arm_group_label>
    <arm_group_label>Multiple dose (MD)</arm_group_label>
    <other_name>NNC0195-0092</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (somapacitan)</intervention_name>
    <description>Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)</description>
    <arm_group_label>Single dose (SD)</arm_group_label>
    <arm_group_label>Multiple dose (MD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking male subjects

          -  BMI (body mass index) between 18.0 and 28.0 kg/m^2, both incl.

          -  Body weight 50 to 100 kg, both incl.

        Exclusion Criteria:

          -  Strenuous exercise within 4 days prior to dosing

          -  Receipt of any investigational medicinal product within 3 months prior to
             randomisation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR,1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

